gefitinib has been researched along with Parotid Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cohen, PR; Jalalat, SZ | 1 |
| Dahse, R; Kosmehl, H | 1 |
2 other study(ies) available for gefitinib and Parotid Neoplasms
| Article | Year |
|---|---|
Gefitinib-associated vitiligo: report in a man with parotid squamous cell carcinoma and review of drug-induced hypopigmentation.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Gefitinib; Humans; Male; Middle Aged; Parotid Neoplasms; Quinazolines; Vitiligo | 2013 |
Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma.
Topics: Aged; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; DNA, Neoplasm; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Parotid Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |